• In late June and early July 2026, Arcturus Therapeutics announced a collaboration with Thermo Fisher Scientific, under which Thermo Fisher will supply integrated Phase 3 manufacturing, clinical research and potential commercial manufacturing services for ARCT-032, an investigational mRNA therapy for cystic fibrosis.
• This agreement aligns Thermo Fisher even more closely with cutting-edge mRNA and rare disease workflows, expanding its role as an end-to-end development and manufacturing partner in complex biologics.
• Next, we'll examine how Thermo Fisher’s deepening role in late-stage mRNA manufacturing through ARCT-032 could influence its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher, you generally need to believe in its role as a diversified picks-and-shovels provider to pharma, biotech and diagnostics, with resilient demand for its tools, consumables and services even when individual end markets are choppy. The Arcturus ARCT-032 collaboration reinforces Thermo Fisher’s end-to-end presence in complex biologics, but it does not materially change the near term focus on lab spending trends and China exposure as key catalysts and risks.

Among recent announcements, the AustinPx KinetiSol agreement is especially relevant, because it broadens Thermo Fisher’s advanced oral drug manufacturing toolkit in a way that echoes the ARCT-032 mRNA deal: both deepen its role as a development-to-commercialization partner. Together, these moves sit alongside upcoming Q2 2026 earnings as important reference points for how well Thermo Fisher is converting its expanded capabilities into growth while managing margin and funding headwinds.

Yet while these partnerships look promising, investors should also be aware that persistent weakness in China and tariff-related margin pressure could...

Thermo Fisher Scientific's narrative projects $54.1 billion revenue and $9.5 billion earnings by 2029. This requires 6.2% yearly revenue growth and about a $2.7 billion earnings increase from $6.8 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $611.56 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Compared with consensus, the most optimistic analysts already expected Thermo Fisher to reach about US$56.0 billion in revenue and US$10.2 billion in earnings by 2029, so this new ARCT-032 partnership could either support that upbeat view or highlight how sensitive those forecasts are to trade and China risks if conditions shift.

Explore 6 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth 6% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.